Peter Bramlage

Summary

Affiliation: Technical University
Country: Germany

Publications

  1. ncbi request reprint Clinical practice and recent recommendations in hypertension management--reporting a gap in a global survey of 1259 primary care physicians in 17 countries
    Peter Bramlage
    Institute for Clinical Pharmacology, Medical Faculty, Dresden, Germany
    Curr Med Res Opin 23:783-91. 2007
  2. ncbi request reprint Recognition and management of overweight and obesity in primary care in Germany
    P Bramlage
    Institute of Clinical Psychology and Psychotherapy, Technical University, 01187 Dresden, Germany
    Int J Obes Relat Metab Disord 28:1299-308. 2004
  3. ncbi request reprint Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled
    Peter Bramlage
    Institute of Clinical Pharmacology, Institute of Clinical Psychology and Psychotherapy, Technical University, Dresden
    Am J Hypertens 17:904-10. 2004
  4. ncbi request reprint [Prevention of cardiovascular disease by blocking the endocannabinoid system]
    Peter Bramlage
    Institut fur Klinische Pharmakologie, Medizinische Fakultat, TU Dresden, Dresden
    Herz 32:560-7. 2007
  5. ncbi request reprint Cardiovascular risk in obese hypertensive patients taking various antihypertensive drugs
    Christoph Schindler
    Institute of Clinical Pharmacology, Technical University, Dresden, Germany
    Clin Drug Investig 27:707-17. 2007
  6. ncbi request reprint Frequency of albuminuria in primary care: a cross-sectional study
    Peter Bramlage
    Institute for Clinical Pharmacology, Medical Faculty, Technical University of Dresden, Dresden, Germany
    Eur J Cardiovasc Prev Rehabil 14:107-13. 2007
  7. pmc Abdominal obesity is associated with microalbuminuria and an elevated cardiovascular risk profile in patients with hypertension
    Martin Thoenes
    Institute for Clinical Pharmacology, Medical Faculty Carl Gustav Carus, Technical University Dresden, Germany
    Vasc Health Risk Manag 5:577-85. 2009
  8. ncbi request reprint [Albuminuria: an indicator of cardiovascular risk]
    Peter Bramlage
    Institut fur Klinische Pharmakologie, Medizinische Fakultat, TU Dresden, Dresden
    Med Klin (Munich) 102:833-43; quiz 844-5. 2007
  9. doi request reprint Blood pressure management in a cohort of hypertensive patients in Germany treated by cardiologists
    Martin Thoenes
    Institute for Clinical Pharmacology, Medical Faculty Carl Gustav Carus, Technical University, Dresden, Germany
    Clin Res Cardiol 100:483-91. 2011
  10. pmc Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy
    Christoph Schindler
    Institute of Clinical Pharmacology, Medical Faculty, Technical University of Dresden, Dresden, Germany
    Vasc Health Risk Manag 3:125-37. 2007

Detail Information

Publications36

  1. ncbi request reprint Clinical practice and recent recommendations in hypertension management--reporting a gap in a global survey of 1259 primary care physicians in 17 countries
    Peter Bramlage
    Institute for Clinical Pharmacology, Medical Faculty, Dresden, Germany
    Curr Med Res Opin 23:783-91. 2007
    ..Therefore, it was hypothesized that physicians' attitude towards high BP, as well as patients' perception and knowledge, may influence actual management of hypertension...
  2. ncbi request reprint Recognition and management of overweight and obesity in primary care in Germany
    P Bramlage
    Institute of Clinical Psychology and Psychotherapy, Technical University, 01187 Dresden, Germany
    Int J Obes Relat Metab Disord 28:1299-308. 2004
    ....
  3. ncbi request reprint Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled
    Peter Bramlage
    Institute of Clinical Pharmacology, Institute of Clinical Psychology and Psychotherapy, Technical University, Dresden
    Am J Hypertens 17:904-10. 2004
    ..The objective of this study was to assess the prevalence of hypertension and the diagnosis, treatment status, and control rates of hypertension in obese patients as compared to patients with normal weight...
  4. ncbi request reprint [Prevention of cardiovascular disease by blocking the endocannabinoid system]
    Peter Bramlage
    Institut fur Klinische Pharmakologie, Medizinische Fakultat, TU Dresden, Dresden
    Herz 32:560-7. 2007
    ....
  5. ncbi request reprint Cardiovascular risk in obese hypertensive patients taking various antihypertensive drugs
    Christoph Schindler
    Institute of Clinical Pharmacology, Technical University, Dresden, Germany
    Clin Drug Investig 27:707-17. 2007
    ..We aimed to assess the risk factor profiles of primary-care patients with obesity and hypertension in order to estimate their fatal CV risk in total and according to use of various antihypertensive drugs...
  6. ncbi request reprint Frequency of albuminuria in primary care: a cross-sectional study
    Peter Bramlage
    Institute for Clinical Pharmacology, Medical Faculty, Technical University of Dresden, Dresden, Germany
    Eur J Cardiovasc Prev Rehabil 14:107-13. 2007
    ....
  7. pmc Abdominal obesity is associated with microalbuminuria and an elevated cardiovascular risk profile in patients with hypertension
    Martin Thoenes
    Institute for Clinical Pharmacology, Medical Faculty Carl Gustav Carus, Technical University Dresden, Germany
    Vasc Health Risk Manag 5:577-85. 2009
    ..The present analysis evaluates the prevalence of microalbuminuria (MAU) and conventional cardiovascular risk factors in relation to measures of general and abdominal obesity...
  8. ncbi request reprint [Albuminuria: an indicator of cardiovascular risk]
    Peter Bramlage
    Institut fur Klinische Pharmakologie, Medizinische Fakultat, TU Dresden, Dresden
    Med Klin (Munich) 102:833-43; quiz 844-5. 2007
    ..The appearance of albumin in the urine is pathologic and should be evaluated within the context of the accompanying cardiovascular risk...
  9. doi request reprint Blood pressure management in a cohort of hypertensive patients in Germany treated by cardiologists
    Martin Thoenes
    Institute for Clinical Pharmacology, Medical Faculty Carl Gustav Carus, Technical University, Dresden, Germany
    Clin Res Cardiol 100:483-91. 2011
    ..The present analysis reports blood pressure treatment and control rates in Germany in patients with hypertension treated by cardiologists...
  10. pmc Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy
    Christoph Schindler
    Institute of Clinical Pharmacology, Medical Faculty, Technical University of Dresden, Dresden, Germany
    Vasc Health Risk Manag 3:125-37. 2007
    ..In addition, the potential therapeutic impact of currently available RAS blocking agents (ACE-1 and ARBs) and new agents still under development (renin-inhibitors) on the RAS-effector peptides is highlighted...
  11. pmc Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiac risk patients: a non interventional study in primary care
    Peter Bramlage
    Institute for Clinical Pharmacology, Medical Faculty Carl Gustav Carus, TU Dresden, Germany
    BMC Cardiovasc Disord 8:30. 2008
    ....
  12. ncbi request reprint Comparison of selective AT1-receptor blockade versus ACE inhibition for restenosis prophylaxis in patients with peripheral occlusive arterial disease after stent angioplasty: a randomized, controlled, proof-of-concept study
    Christoph Schindler
    Institute of Clinical Pharmacology, Medical Faculty, Technical University Dresden, Germany
    Angiology 58:710-6. 2007
    ..Further prospective studies in patients are required to confirm these results...
  13. ncbi request reprint [Antihypertensive drug utilization in obese patients]
    Peter Bramlage
    Institut fur Klinische Pharmakologie, Technische Universitat Dresden, Dresden
    Med Klin (Munich) 100:804-9. 2005
    ..In spite of the frequency and the difficulties in treating these patients to goal, there are no recent data on the prescription of antihypertensive drugs in primary care in this patient population...
  14. pmc Cardiac implications of hypoglycaemia in patients with diabetes - a systematic review
    Markolf Hanefeld
    Study Centre Professor Hanefeld, GWT, TU Dresden, Dresden, Germany
    Cardiovasc Diabetol 12:135. 2013
    ..This review aims to summarize the available data on how hypoglycaemia may affect CV risk in patients with diabetes...
  15. ncbi request reprint [The use of guidelines in the primary care management of hypertension and diabetes]
    Nicole Wagner
    Institut für Klinische Pharmakologie und Forschungsverbund Public Health Sachsen und Sachsen Anhalt e V, TU Dresden
    Soz Praventivmed 49:261-8. 2004
    ..The paper examines to what degree German primary care physicians know and work along the rules established in guidelines for arterial hypertension and diabetes mellitus...
  16. ncbi request reprint Comparison of inhibitory effects of irbesartan and atorvastatin treatment on the renin angiotensin system (RAS) in veins: a randomized double-blind crossover trial in healthy subjects
    Christoph Schindler
    Institute of Clinical Pharmacology, Medical Faculty of the University of Technology, Fiedlerstrasse 27, D 01307 Dresden, Germany
    J Clin Pharmacol 47:112-20. 2007
    ..The data indicate that atorvastatin does not inhibit Ang II-induced venoconstriction in vivo and point toward a supportive role of Ang-(1-7) in contributing to the antihypertensive and beneficial vascular effects of irbesartan...
  17. ncbi request reprint Drug interactions with angiotensin receptor blockers
    Steffen Böhler
    Technical University of Dresden, Institute of Clinical Pharmacology, Medical Faculty Carl Gustav Carus, Fiedlerstrasse 27, D 01307 Dresden, Germany
    Expert Opin Drug Saf 4:7-18. 2005
    ....
  18. pmc Hypertension control and cardiometabolic risk: a regional perspective
    Martin Thoenes
    Institute for Clinical Pharmacology, Medical Faculty Carl Gustav Carus, Technical University Dresden, 01307 Dresden, Germany
    Cardiol Res Pract 2012:925046. 2012
    ..Elevated SBP/DBP and uncontrolled hypertension were associated with increasing BMI, LDL-cholesterol, triglycerides, and HbA1c, both globally and regionally...
  19. doi request reprint Predictors of response to early basal insulin treatment in patients with type 2 diabetes--the EARLY experience
    Markolf Hanefeld
    1 Study Centre Professor Hanefeld, Company for the Transfer of Knowledge and Technology of the Dresden University of Technology, Dresden, Germany
    Diabetes Technol Ther 16:241-6. 2014
    ..5% (58 mmol/mol) at baseline despite 3 months of maximum tolerated dose of metformin under daily conditions...
  20. doi request reprint Benefits and risks of preventing thromboembolism with enoxaparin in patients with general surgery in real world--the CLEVER study
    Sebastian M Schellong
    Klinikum Friedrichstadt, Dresden, Germany
    Clin Appl Thromb Hemost 19:282-8. 2013
    ..We aimed to document enoxaparin use in real world and identify the risk factors for bleeding complications...
  21. pmc Bioequivalence study of three ibuprofen formulations after single dose administration in healthy volunteers
    Peter Bramlage
    Institute for Clinical Pharmacology, Medical Faculty Carl Gustav Carus, Technical University Dresden, Fiedlerstrasse 27, 01307 Dresden, Germany
    BMC Pharmacol 8:18. 2008
    ..Therefore the design of a randomized, open label, multiple sequence cross-over study with a wash-out period of 7-10 days was used...
  22. pmc Dyslipidemia in primary care--prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS)
    Elisabeth Steinhagen-Thiessen
    Charite Universitatsmedizin Berlin, Germany
    Cardiovasc Diabetol 7:31. 2008
    ..Although being mainly a prevention tool, its thresholds are difficult to meet in clinical practice, especially primary care...
  23. pmc Prevalence of obesity in primary care using different anthropometric measures--results of the German Metabolic and Cardiovascular Risk Project (GEMCAS)
    Hans Hauner
    Else Kröner Fresenius Zentrum für Ernährungsmedizin, Technical University Munich, Klinikum rechts der Isar, Ismaninger Str 22, 81675 Munchen, Germany
    BMC Public Health 8:282. 2008
    ....
  24. pmc First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation
    Walter Zidek
    Medical Department IV, University Hospital Charite, Campus Benjamin Franklin, Berlin, Germany
    Cardiovasc Diabetol 7:22. 2008
    ..Ramipril is an ACE inhibitor (ACEi), that has been shown to reduce cardiovascular events in high risk patients and post-hoc analyses of the HOPE trial have provided evidence for its beneficial action in the prevention of diabetes...
  25. ncbi request reprint Quality of life in hypertension management using olmesartan in primary care
    Andre C Schmidt
    Charite Universitatsmedizin Berlin, Department of Clinical Pharmacology and Toxicology, CharitéCentrum für Therapieforschung, Chariteplatz 1, D 10117 Berlin, Germany
    Expert Opin Pharmacother 9:1641-53. 2008
    ..As this is the prerequisite for cardiovascular risk reduction, QoL was investigated using highly tolerable drugs (such as olmesartan)...
  26. ncbi request reprint Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH
    Michael Bohm
    Klinik für Innere Medizin III Cardiology, Angiology and Intensive Care Medicine, University of the Saarland, Homburg Saar, Germany
    J Hypertens 26:18-25. 2008
    ..In patients in sinus rhythm (n = 18 900) the relationship between increased heart rate and the prevalence of MAU was analysed...
  27. pmc Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients
    Ulrich Kintscher
    Center for Cardiovascular Research, Institute of Pharmacology, Charite, Berlin, Germany
    Cardiovasc Diabetol 6:12. 2007
    ..Therefore the efficacy, safety and metabolic profile of Irbesartan either as monotherapy or in combination therapy was assessed in patients with the metabolic syndrome in a large observational cohort in primary care...
  28. ncbi request reprint Hypophagic effect of the angiotensin AT1 receptor antagonist irbesartan in rats
    Jörg Peter Voigt
    Institute of Pharmacology and Toxicology, School of Veterinary Medicine, Freie Universitat Berlin, Koserstrasse 20, 14195 Berlin, Germany
    Eur J Pharmacol 564:131-7. 2007
    ..In conclusion, the present study demonstrates a hypophagic effect of the angiotensin AT(1) receptor antagonist irbesartan that cannot be attributed to sedation or antidipsic effects of the drug...
  29. ncbi request reprint Low-grade albuminuria and cardiovascular risk : what is the evidence?
    Roland E Schmieder
    Medizinische Klinik 4, Nephrologie und Hypertensiologie, Universitatsklinikum Erlangen, Krankenhausstrasse 12, 91054, Erlangen, Germany
    Clin Res Cardiol 96:247-57. 2007
    ..MA is modifiable, and the inhibition of the renin-angiotensin system by ACE inhibitors and AT1 receptor antagonists has been shown to result in a lower incidence of cardiovascular events...
  30. pmc Impact of 4 different definitions used for the assessment of the prevalence of the Metabolic Syndrome in primary healthcare: The German Metabolic and Cardiovascular Risk Project (GEMCAS)
    Susanne Moebus
    Institute for Medical Informatics, Biometry and Epidemiology, University Hospital, Essen, Germany
    Cardiovasc Diabetol 6:22. 2007
    ..Aim here is to assess the prevalence of the MetSyn in primary health care and to investigate the impact of four different definitions of the MetSyn on the determined prevalence with regard to age, gender and socio-economic status...
  31. ncbi request reprint BP goal achievement in patients with uncontrolled hypertension : results of the treat-to-target post-marketing survey with irbesartan
    Joachim Schrader
    Department of Internal Medicine, St Josefs Hospital, Cloppenburg, Germany
    Clin Drug Investig 27:783-96. 2007
    ....
  32. ncbi request reprint Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study
    Michael Bohm
    Cardiology, Angiology and Intensive Care Medicine, University of the Saarland, Homburg, Saar, Germany
    J Hypertens 25:2317-24. 2007
    ..A secondary objective was to establish a correlation between MAU and known cardiovascular risk factors...
  33. ncbi request reprint [Long-term follow-up of cardiovascular risk markers in patients with hypertension. Rationale, design, and baseline characteristics of the i-Search Plus Registry]
    Ulrich Tebbe
    Fachbereich Herz Kreislauf Lunge Niere, Klinikum Lippe GmbH, Detmold
    Med Klin (Munich) 102:824-32. 2007
    ..Blockade of the renin-angiotensin system (RAS) has been shown to reduce some of these risk markers in clinical trials, but validation of their time course and role in clinical practice is still pending...
  34. ncbi request reprint [Cardiometabolic high risk patients with abdominal obesity. Frequency and risk factor profile in primary care]
    Jurgen Scholze
    Universitatsklinikum Charite, Campus Charite Mitte, Medizinische Poliklinik, Berlin
    MMW Fortschr Med 149:103-10. 2007
    ....
  35. ncbi request reprint High prevalence and poor control of hypertension in primary care: cross-sectional study
    Arya M Sharma
    Franz Volhard Clinic Charité, Berlin, Germany
    J Hypertens 22:479-86. 2004
    ....
  36. ncbi request reprint Prevalence of deep vein thrombosis (DVT) in non-surgical patients at hospital admission
    Holger Lawall
    Department of Internal Medicine Vascular Medicine, Hospital Karlsbad Langensteinbach, Affiliated Teaching Hospital, University of Heidelberg, Guttmannstrasse 1, 76307 Karlsbad, Germany
    Thromb Haemost 98:765-70. 2007
    ..These data demonstrate the high risk of DVT is in non-surgical patients. Early prophylaxis has to be considered in internal medicine patients especially in the elderly...